| ORIGINAL ARTICLE
|Year : 2015 | Volume
| Issue : 5 | Page : 697--701
The effect of citicoline on stroke: A comparative study from the Eastern part of India
Saikat Ghosh1, Somak Kumar Das2, Tanusree Nath3, Kartik Chandra Ghosh4, Ramesh Bhattacharyya4, Gouranga Prosad Mondal4
1 Department of Neuromedicine, Calcutta National Medical College, Kolkata, West Bengal, India
2 Department of Medicine, College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India
3 Department of Medicine, PGIMER and ESIC Hospital ODC (EZ), Joka, West Bengal, India
4 Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India
Background: Citicoline is a novel neuroprotective agent used in acute stroke with a significantly favorable outcome.
Materials and Methods: A hundred patients who suffered from either an ischemic and hemorrhagic stroke and who presented to the hospital within 48 h of stroke onset were enrolled for the study. Of these 100 patients (age- and sex-matched), 50 patients were treated with citicoline along with the standard stroke management and considered as 'cases'. The other 50 patients who were administered the standard stroke treatment were considered as 'controls.' The baseline parameters of the patients was assessed using the National Institute of Health Stroke Scale. The patients were reassessed at follow up at the end of the 1st and 3rd month of the commencement of the therapy and their outcome was evaluated by the Barthel Index score (BI).
Results: The mean BI scores of all categories at the 1st and 3rd month were significantly higher in the citicoline treatment group (P < 0.001 at the 1st month and P = 0.002 at the 3rd month). An analysis of the categorized BI score showed that there was a significant difference in the number of patients in the categorized BI score (85–100) (at the 1st month follow-up: 0% in control vs. 7% in case group [P < 0.05]; and, at the 3rd month follow-up: 10% in control vs. 36% in citicoline case group [P < 0.05]). In the subgroup analysis, both patients suffering from either ischemic and hemorrhagic stroke (including all categories of BI score) in the citicoline treatment group showed a significantly higher mean BI score at the 1st month (ischemic: P = 0.003, hemorrhagic: P =0.04) and also at the end of the 3rd month (ischemic: P = 0.03, hemorrhagic: P = 0.03). An analysis of the categorized BI score (85–100) at the end of the 3rd month in both the hemorrhagic as well as the ischemic subgroups showed a significant incidence of improvement in the citicoline group compared with the control group (hemorrhagic-- control: 6.66% vs. case: 31.81%, P < 0.05 and ischemic-- control: 11.41% vs. case: 35.71%, P < 0.05).
Conclusion: In patients suffering from stroke and presenting within 48 h of onset, treatment with citicholine increases the probability of complete recovery and a favorable outcome at the 1st month and at the end of the 3rd month in all the stroke groups.
Somak Kumar Das
Flat No. A-10, Millennium Apartment, 23, Kalibari Lane, Jadavpur, Kolkata - 700. 032, West Bengal
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*